9 completed, 1 unknown. 6 Phase 3, 2 Phase 2, 1 Early Phase 1, 1 Phase 1.
By phase and status
Follow SkyePharma AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
The Gastric Residence Time (GRT) of Soctec Capsule After a Standardized Breakfast
Soctec - Healthy | Early Phase 1 | Unknown | SkyePharma AG | 15 | 2014-09-01 | 2015-01-09 |
Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma
fluticasone propionate, formoterol fumarate - Mild to Moderate Asthma | Phase 2 | Completed | SkyePharma AG | 39 | 2008-09-01 | 2010-08-27 |
A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005
SKP FlutiForm HFA pMDI - Asthma | Phase 3 | Completed | SkyePharma AG | 280 | 2008-09-01 | 2011-06-23 |
A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands
FlutiForm 250/10 ug, FlutiForm 100/10 ug, Oral Prednisone 10mg - Asthma | Phase 1 | Completed | SkyePharma AG | 160 | 2008-04-01 | 2008-12-01 |
A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults
FlutiForm 250/10, SKP-Fluticasone, Flovent Fluticasone HFA - Asthma | Phase 3 | Completed | SkyePharma AG | 438 | 2008-03-01 | 2010-08-27 |
Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma
Fluticasone propionate/formoterol fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10 - Asthma | Phase 3 | Completed | SkyePharma AG | 475 | 2006-07-01 | 2011-06-23 |
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma
Fluticasone propionate/Formoterol fumarate 250/10, Placebo, Fluticasone propionate/Formoterol fumarate 100/10 - Asthma | Phase 3 | Completed | SkyePharma AG | 557 | 2006-06-01 | 2011-06-23 |
Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma
Fluticasone propionate/Formoterol Fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10 - Asthma | Phase 3 | Completed | SkyePharma AG | 357 | 2006-06-01 | 2011-06-23 |
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma
Fluticasone propionate/formoterol fumarate - Asthma | Phase 3 | Completed | SkyePharma AG | 400 | 2006-03-01 | 2010-08-27 |
Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients
fluticasone propionate, formoterol fumarate - Asthma | Phase 2 | Completed | SkyePharma AG | 64 | 2004-10-01 | 2011-06-23 |
Conditions studied
Asthma (9)
Interventions
Fluticasone (8) · Formoterol Fumarate (4) · fluticasone-formoterol (4) · Prednisone (1)
Countries
United States (7) · Romania (3) · Canada (2) · Hungary (2) · Mexico (2) · Peru (2) · Poland (2) · Ukraine (2) · United Kingdom (2) · Argentina (1) · Chile (1) · Germany (1) · Ireland (1) · Puerto Rico (1) · South Africa (1)
Top investigators
Karim Bagate, PhD (1) · Thao T Doan, MD (1)
Results publications
PMID 23078148, PMID 23098325, PMID 23865726, PMID 23870606